Drug
MDX-010
MDX-010 is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
20%(1 trials)
Phase Distribution
Ph phase_1
4
80%
Ph phase_2
1
20%
Phase Distribution
4
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (80.0%)
Phase 21 (20.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
Vaccine and Antibody Treatment of Prostate Cancer
NCT00113984
completedphase_1
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
NCT03407105
completedphase_1
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00323882
completedphase_2
Study of MDX-010 in Stage IV Breast Cancer
NCT00083278
completedphase_1
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00729950
Clinical Trials (5)
Showing 5 of 5 trials
NCT00113984Phase 1
Vaccine and Antibody Treatment of Prostate Cancer
NCT03407105Phase 1
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
NCT00323882Phase 1
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00083278Phase 2
Study of MDX-010 in Stage IV Breast Cancer
NCT00729950Phase 1
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5